Abstract
MONOCLONAL anti-CD3 antibodies have been widely used for the treatment of acute allograft rejection (AR) episodes and for induction therapy (IT). Their impact on long-term survival has been demonstrated mainly in high-risk patients. Recent data have suggested that this antibody may be used at reduced doses without compromising its efficacy. We report here our experience with 58 kidney transplant (Tx) patients in which low daily doses of OKT3 were used as IT or for the treatment of severe or steroid-resistant AR.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
